查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1322232

核醫學市場 - 全球行業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Nuclear Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 187 Pages | 商品交期: 2-10個工作天內

價格

核醫學市場 - 報告範圍

TMR 關於全球核醫學市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球核醫學市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。該報告還提供了2023年至2031年全球核醫學市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領袖和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解核醫學市場。

該報告深入研究了全球核醫學市場的競爭格局。全球核醫學市場的主要參與者已經確定，並且每一個參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球核醫學市場參與者的屬性。

目錄

第一章：前言

第 2 章：假設和研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 技術進步
  • FDA 批准的放射性同位素列表
  • 主要國家的中心數量
  • COVID-19 大流行對行業的影響

第 6 章：全球市場分析與預測：按類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按類型，2017-2031
    • 診斷
      • PECT放射性藥物
      • PET放射性藥物
    • 治療性
      • 阿爾法發射器
      • 貝塔發射器
      • 近距離放射治療同位素
  • 市場吸引力分析：按類型

第 7 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按應用分類，2017-2031
    • 心臟病學
    • 神經病學
    • 腫瘤學
    • 肺科
    • 胃腸病學
    • 其他
  • 市場吸引力分析：按應用

第 8 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 醫院
    • 診斷中心
      • 個人練習
      • 小組練習
    • 研究機構
  • 市場吸引力分析：按最終用戶

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（按公司層級和規模）
  • 市場佔有率分析：按公司分類，2022 年
  • 公司簡介
    • GE Healthcare
    • Siemens Healthineers
    • Philips Healthcare
    • Cardinal Health
    • Bracco Imaging SpA
    • Curium Pharma
    • Eckert & Ziegler
    • Jubilant Radiopharma
    • Lantheus Medical Imaging
    • Nordion, Inc.
    • Advanced Accelerator Applications (AAA)
    • IBA Radiopharma Solutions
    • NorthStar Medical Radioisotopes
    • Polatom
    • Isotopia Molecular Imaging
Product Code: TMRGL4672

Nuclear Medicine Market - Scope of Report

TMR's report on the global Nuclear Medicine Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Nuclear Medicine Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Nuclear Medicine Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Nuclear Medicine Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Nuclear Medicine Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Nuclear Medicine Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Nuclear Medicine Market.

The report delves into the competitive landscape of the global Nuclear Medicine Market. Key players operating in the global Nuclear Medicine Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Nuclear Medicine Market profiled in this report.

Key Questions Answered in Global Nuclear Medicine Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Nuclear Medicine Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Nuclear Medicine Market - Research Objectives and Research Approach

The comprehensive report on the global Nuclear Medicine Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Nuclear Medicine Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Nuclear Medicine.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nuclear Medicine Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nuclear Medicine Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. List of FDA Approved Radioisotopes
  • 5.3. No. of Nuclear Medicine Centers in Major Countries
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Nuclear Medicine Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Diagnostic Nuclear Medicine
      • 6.3.1.1. PECT Radiopharmaceuticals
      • 6.3.1.2. PET Radiopharmaceuticals
    • 6.3.2. Therapeutic Nuclear Medicine
      • 6.3.2.1. Alpha Emitters
      • 6.3.2.2. Beta Emitters
      • 6.3.2.3. Brachytherapy Isotopes
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Nuclear Medicine Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Cardiology
    • 7.3.2. Neurology
    • 7.3.3. Oncology
    • 7.3.4. Pulmonology
    • 7.3.5. Gastroenterology
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Nuclear Medicine Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Diagnostic Centers
      • 8.3.2.1. Individual Practice
      • 8.3.2.2. Group Practice
    • 8.3.3. Research Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Nuclear Medicine Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Nuclear Medicine Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type, 2017-2031
    • 10.2.1. Diagnostic Nuclear Medicine
      • 10.2.1.1. PECT Radiopharmaceuticals
      • 10.2.1.2. PET Radiopharmaceuticals
    • 10.2.2. Therapeutic Nuclear Medicine
      • 10.2.2.1. Alpha Emitters
      • 10.2.2.2. Beta Emitters
      • 10.2.2.3. Brachytherapy Isotopes
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Cardiology
    • 10.3.2. Neurology
    • 10.3.3. Oncology
    • 10.3.4. Pulmonology
    • 10.3.5. Gastroenterology
    • 10.3.6. Others
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Diagnostic Centers
      • 10.4.2.1. Individual Practice
      • 10.4.2.2. Group Practice
    • 10.4.3. Research Institutes
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Nuclear Medicine Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Diagnostic Nuclear Medicine
      • 11.2.1.1. PECT Radiopharmaceuticals
      • 11.2.1.2. PET Radiopharmaceuticals
    • 11.2.2. Therapeutic Nuclear Medicine
      • 11.2.2.1. Alpha Emitters
      • 11.2.2.2. Beta Emitters
      • 11.2.2.3. Brachytherapy Isotopes
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Cardiology
    • 11.3.2. Neurology
    • 11.3.3. Oncology
    • 11.3.4. Pulmonology
    • 11.3.5. Gastroenterology
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Diagnostic Centers
      • 11.4.2.1. Individual Practice
      • 11.4.2.2. Group Practice
    • 11.4.3. Research Institutes
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Nuclear Medicine Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Diagnostic Nuclear Medicine
      • 12.2.1.1. PECT Radiopharmaceuticals
      • 12.2.1.2. PET Radiopharmaceuticals
    • 12.2.2. Therapeutic Nuclear Medicine
      • 12.2.2.1. Alpha Emitters
      • 12.2.2.2. Beta Emitters
      • 12.2.2.3. Brachytherapy Isotopes
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Cardiology
    • 12.3.2. Neurology
    • 12.3.3. Oncology
    • 12.3.4. Pulmonology
    • 12.3.5. Gastroenterology
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Hospitals
    • 12.4.2. Diagnostic Centers
      • 12.4.2.1. Individual Practice
      • 12.4.2.2. Group Practice
    • 12.4.3. Research Institutes
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Type
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Nuclear Medicine Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Diagnostic Nuclear Medicine
      • 13.2.1.1. PECT Radiopharmaceuticals
      • 13.2.1.2. PET Radiopharmaceuticals
    • 13.2.2. Therapeutic Nuclear Medicine
      • 13.2.2.1. Alpha Emitters
      • 13.2.2.2. Beta Emitters
      • 13.2.2.3. Brachytherapy Isotopes
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Cardiology
    • 13.3.2. Neurology
    • 13.3.3. Oncology
    • 13.3.4. Pulmonology
    • 13.3.5. Gastroenterology
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Hospitals
    • 13.4.2. Diagnostic Centers
    • 13.4.3. Research Institutes
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Nuclear Medicine Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Diagnostic Nuclear Medicine
      • 14.2.1.1. PECT Radiopharmaceuticals
      • 14.2.1.2. PET Radiopharmaceuticals
    • 14.2.2. Therapeutic Nuclear Medicine
      • 14.2.2.1. Alpha Emitters
      • 14.2.2.2. Beta Emitters
      • 14.2.2.3. Brachytherapy Isotopes
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Cardiology
    • 14.3.2. Neurology
    • 14.3.3. Oncology
    • 14.3.4. Pulmonology
    • 14.3.5. Gastroenterology
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Hospitals
    • 14.4.2. Diagnostic Centers
      • 14.4.2.1. Individual Practice
      • 14.4.2.2. Group Practice
    • 14.4.3. Research Institutes
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Type
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2022
  • 15.3. Company Profiles
    • 15.3.1. GE Healthcare
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Type Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Siemens Healthineers
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Type Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Philips Healthcare
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Type Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Cardinal Health
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Type Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Bracco Imaging S.p.A.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Type Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Curium Pharma
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Type Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Eckert & Ziegler
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Type Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Jubilant Radiopharma
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Type Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Lantheus Medical Imaging
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Type Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Nordion, Inc.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Type Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Advanced Accelerator Applications (AAA)
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Type Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. IBA Radiopharma Solutions
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Type Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview
    • 15.3.13. NorthStar Medical Radioisotopes
      • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.13.2. Type Portfolio
      • 15.3.13.3. Financial Overview
      • 15.3.13.4. SWOT Analysis
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Polatom
      • 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.14.2. Type Portfolio
      • 15.3.14.3. Financial Overview
      • 15.3.14.4. SWOT Analysis
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Isotopia Molecular Imaging
      • 15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.15.2. Type Portfolio
      • 15.3.15.3. Financial Overview
      • 15.3.15.4. SWOT Analysis
      • 15.3.15.5. Strategic Overview

List of Table

  • Table 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 07: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 09: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 11: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 15: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 19: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figure

  • Figure 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Nuclear Medicine Market Value Share, by Type, 2022
  • Figure 03: Global Nuclear Medicine Market Value Share, by Application, 2022
  • Figure 04: Global Nuclear Medicine Market Value Share, by End-user, 2022
  • Figure 05: Global Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 06: Global Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 07: Global Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 08: Global Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
  • Figure 09: Global Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 10: Global Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 13: Global Nuclear Medicine Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 14: Global Nuclear Medicine Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 15: North America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: North America Nuclear Medicine Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 17: North America Nuclear Medicine Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 18: North America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 19: North America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 20: North America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 21: North America Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
  • Figure 22: North America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 23: North America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 24: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: Europe Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Europe Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Europe Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 28: Europe Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
  • Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 31: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 35: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 36: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 37: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
  • Figure 38: Asia Pacific Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 39: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 40: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Latin America Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Latin America Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Latin America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 44: Latin America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 45: Latin America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 46: Latin America Nuclear Medicine Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 47: Latin America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 48: Latin America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 49: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 51: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 52: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 53: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 54: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 55: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
  • Figure 56: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 57: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 58: Global Nuclear Medicine Market Share Analysis By Company (2022)